Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

MRK's focus shifts beyond Keytruda in Q4 as investors watch new products Capvaxive and Winrevair, as well as Animal Health business sales performance.

Eikon ‍Therapeutics (EIKN), a cancer drug developer led by Merck (MRK) veteran Roger Perlmutter, has filed for its U.S. IPO ...

Merck & Co. is no longer in talks to acquire biotech firm Revolution Medicines Inc. after the two companies couldn’t agree on ...

The drugmaker had recently been in discussions to acquire RevMed in a deal that could have valued the cancer-drug biotech at ...

A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...

The pharmaceutical giant had been in talks to buy the cancer drug developer in a transaction that could have valued ...

Merck paused acquisition discussions with Revolution Medicines after the two sides could not agree on valuation. The halted ...

Moderna and Merck’s cancer vaccine reduced the risk of relapse or death for melanoma patients, five-year data from a Phase 2b ...

The company’s previous CCO was Cristal Downing, who joined Insulet as chief corporate affairs officer late last year.

Jan 25 (Reuters) - Merck is no longer in discussions to buy cancer drug developer Revolution Medicines, the Wall Street ...